RHYTHM PHARMACEUTICALS INC (RYTM)
US76243J1051 - Common Stock
Taking everything into account, RYTM scores 2 out of 10 in our fundamental rating. RYTM was compared to 586 industry peers in the Biotechnology industry. RYTM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RYTM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RYTM had negative earnings in the past year.
In the past year RYTM has reported a negative cash flow from operations.
RYTM had negative earnings in each of the past 5 years.
In the past 5 years RYTM always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -105.88%, RYTM is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
RYTM has a Return On Equity of -444.72%. This is in the lower half of the industry: RYTM underperforms 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.88% | ||
| ROE | -444.72% | ||
| ROIC | N/A |
ROA(3y)-41.33%
ROA(5y)-48.24%
ROE(3y)-67.27%
ROE(5y)-66.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of RYTM (88.38%) is better than 92.14% of its industry peers.
The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.38% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
RYTM has more shares outstanding than it did 1 year ago.
RYTM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RYTM is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.83, we must say that RYTM is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.83, RYTM perfoms like the industry average, outperforming 54.70% of the companies in the same industry.
A Debt/Equity ratio of 1.74 is on the high side and indicates that RYTM has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.74, RYTM is doing worse than 81.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.83 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
RYTM has a Current Ratio of 4.35. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.35, RYTM perfoms like the industry average, outperforming 46.84% of the companies in the same industry.
RYTM has a Quick Ratio of 4.20. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
RYTM has a Quick ratio (4.20) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.35 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
RYTM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.21%.
Looking at the last year, RYTM shows a very strong growth in Revenue. The Revenue has grown by 173.49%.
EPS 1Y (TTM)-38.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-155.43%
Revenue 1Y (TTM)173.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q126.41%
3.2 Future
RYTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.49% yearly.
The Revenue is expected to grow by 69.02% on average over the next years. This is a very strong growth
EPS Next Y-31.04%
EPS Next 2Y16.57%
EPS Next 3Y25.8%
EPS Next 5Y37.49%
Revenue Next Year70.31%
Revenue Next 2Y62.25%
Revenue Next 3Y67.48%
Revenue Next 5Y69.02%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RYTM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RYTM's earnings are expected to grow with 25.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.57%
EPS Next 3Y25.8%
5. Dividend
5.1 Amount
RYTM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RHYTHM PHARMACEUTICALS INC
NASDAQ:RYTM (5/17/2024, 7:24:53 PM)
After market: 37.96 0 (0%)37.96
-1.21 (-3.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.31B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.88% | ||
| ROE | -444.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.38% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.74 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.35 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-38.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-31.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)173.49%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y